NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The International Journal of Tuberculosis and Lung Disease

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 20392357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo

  2009cited by this paper
• Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.

  2008cited by this paper
• Effect of acute and repeated exposure to low doses of hydrazine on hepatic microsomal enzymes and biochemical parameters in vivo

  2007cited by this paper
• Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.

  2007cited by this paper
• CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

  2006cited by this paper
• Adverse reactions to first-line antituberculosis drugs

  2006cited by this paper
• Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities.

  2004cited by this paper
• Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

  2003cited by this paper
• Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug‐induced hepatitis

  2003cited by this paper
• Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

  2002cited by this paper
• Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis

  2002cited by this paper
• Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

  2001cited by this paper
• Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A

  2001cited by this paper
• Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.

  2000cited by this paper
• Antituberculosis drug‐related liver dysfunction in chronic hepatitis B infection

  2000cited by this paper
• In vivo modulation of CYP enzymes by quinidine and rifampin

  2000cited by this paper
• A prospective clinical study of isoniazid‐rifampicin‐pyrazinamide‐induced liver injury in an area endemic for hepatitis B

  1997cited by this paper
• Isoniazid-related hepatitis.

  1997cited by this paper
• Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.

  1996cited by this paper
• Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy.

  1996cited by this paper
• Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

  1995cited by this paper
• In vitro microsomal metabolism of hydrazine.

  1995cited by this paper
• Inhibition and induction of cytochrome P4502E1‐catalyzed oxidation by isoniazid in humans

  1993cited by this paper
• Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

  1992cited by this paper
• Criteria of drug-induced liver disorders. Report of an international consensus meeting.

  1990cited by this paper
• Isoniazid hepatitis among pregnant and postpartum Hispanic patients.

  1989cited by this paper
• Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.

  1989cited by this paper
• Characterization of three highly purified cytochromes P-450 from hepatic microsomes of adult male rats.

  1984cited by this paper
• The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450.

  1980cited by this paper
• Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

  1978cited by this paper
• Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

  1976cited by this paper
• Genetical and Geographic Studies on Isoniazid Inactivation

  1961cited by this paper

• The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.

  2026cites this paper
• CYP2E1 POLYMORPHISMS AND SUSCEPTIBILITY TO ANTI-TUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY IN INDONESIA POPULATION

  2025cites this paper
• SARS-CoV-2 Mediated Dysregulation of Drug Processing Genes is Dependent on Pathogenic Variants, Target Site of Infection, Age, and Sex

  2025cites this paper
• Incidence, outcomes, and risk factors of antituberculosis drugs induced liver injury in Thailand: A retrospective cohort study

  2024cites this paper
• Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations

  2024cites this paper
• An Insight into Different Experimental Models used for Hepatoprotective Studies: A Review.

  2024cites this paper
• Polymorphism of CYP3A4*18 is associated with anti-tuberculosis drug-induced hepatotoxicity.

  2024cites this paper
• Pharmacogenetic Analysis of an 8-Year Old Girl with Reye Syndrome Associated with Use of Naproxen

  2023cites this paper
• Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury

  2022cites this paper
• Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis

  2022cites this paper
• Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.

  2022cites this paper
• NAT2 and CYP2E1 polymorphisms and antituberculosis drug‐induced hepatotoxicity in Peruvian patients

  2022cites this paper
• Pyrazinamide related prolonged drug-induced liver injury: A case report

  2022cites this paper
• Variable Doses of Nigella sativa in Isoniazid Induced Liver Toxicity in Rabbits

  2022cites this paper
• Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients

  2021cites this paper
• Pharmacokinetic population of isoniazid in Tunisian tuberculosis patients.

  2021cites this paper
• A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosingfor tuberculosis treatment

  2021cites this paper
• Genetic Polymorphism of Drug‐Metabolizing Enzymes and Drug Transporters in Drug Toxicity

  2021cites this paper
• Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs

  2021cites this paper
• Hepatotoxicity Risk Profile of Indonesian Due to Polymorphism of NAT2 and CYP2E1 in Isoniazid Metabolism

  2021cites this paper
• The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.

  2021cites this paper
• CORRELATION OF GENETIC POLYMORPHISM IN UGT1A1, SLCO1B1, NAT2, AND CYP2E1 WITH HEPATOTOXICITY

  2021cites this paper
• The role of NAT2 polymorphism and methylation in anti‐tuberculosis drug‐induced liver injury in Mongolian tuberculosis patients

  2020cites this paper
• Determination of organ specific pharmacokinetic data for the anti-tuberculosis drugs in guinea pigs using microdialysis

  2019cites this paper
• NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.

  2019cites this paper
• Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity

  2019cites this paper
• Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population

  2019cites this paper
• Clinical and Molecular Risk Factors of Anti-tubercular Therapy Induced Hepatitis.

  2019cites this paper
• NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis

  2019cites this paper
• Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.

  2019cites this paper
• Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis

  2019cites this paper
• Polymorphisms NAT 2 , CYP 2 E 1 , GSTM 1 and GSTT 1

  2018cites this paper
• Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

  2018cites this paper
• Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence

  2018cites this paper
• CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis

  2018cites this paper
• NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

  2018cites this paper
• The association between the NAT2 genetic polymorphisms and risk of DILI during anti‐TB treatment: a systematic review and meta‐analysis

  2018cites this paper
• Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

  2018cites this paper
• Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?

  2018cites this paper
• Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI)

  2018cites this paper
• Drugs and Toxins

  2018cites this paper
• Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI)

  2018cites this paper
• Severe Skin Rash and Liver Toxic Effects Caused By First-Line Anti-Tuberculosis Drugs: A Case Report

  2017cites this paper
• Effect of gene–gene and gene–environment interactions associated with antituberculosis drug-induced hepatotoxicity

  2017cites this paper
• Analysis of GSTM1 Deletion on Adult Pulmonary Tuberculosis Patients

  2017cites this paper
• Acetylator Status on Tuberculosis Patients Receiving Isoniazid-Contained Antituberculosis Regiment

  2017cites this paper
• N-Acetyl Transferase (NAT) 2 Polymorphisms and Susceptibility to Antituberculosis Drug-induced Hepatotoxicity in Indonesia

  2017cites this paper
• Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity.

  2017cites this paper
• Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)

  2017cites this paper
• Analysis of GSTM 1 Deletion on Adult Pulmonary Tuberculosis Patients

  2017cites this paper
• Drug-Induced Liver Disease

  2017cites this paper
• IBL Conference 2017-Proceedings CYP 2 E 1 genotype and transaminase level of tuberculosis patients receiving fixed dose combination of antituberculosis I

  2017influential citation
• Drug metabolism and liver disease: a drug–gene–environment interaction

  2017cites this paper
• HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians

  2017cites this paper
• Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients

  2017cites this paper
• The challenges of pharmacokinetic variability of first-line anti-TB drugs

  2017influential citation
• Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients

  2016cites this paper
• Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.

  2016cites this paper
• NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.

  2016cites this paper
• PharmGKB summary: isoniazid pathway, pharmacokinetics

  2016cites this paper
• Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines

  2016cites this paper
• NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis

  2016cites this paper
• Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review

  2016cites this paper
• Update meta‐analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug‐induced hepatotoxicity: evidence from 26 studies

  2016cites this paper
• The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats

  2016cites this paper
• A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy

  2016cites this paper
• NAT2 Genotype Pattern among Tuberculosis Patients Receiving Fixed-Dose Combination of Antituberculosis

  2016influential citation
• CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.

  2016cites this paper
• Evaluation of cytochrome P4502E1 polymorphisms in healthy adult Western Indians and patients with antituberculous drug-induced hepatotoxicity

  2016cites this paper
• NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs

  2016cites this paper
• Predominance of N-acetyl transferase 2 slow acetylator alleles in children less than ten years experiencing adverse treatment events following artemisinin-based combination therapy in North and South West Regions of Cameroon

  2016cites this paper
• Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2

  2016cites this paper
• A Homogenizing Process of Selection Has Maintained an “Ultra-Slow” Acetylation NAT2 Variant in Humans

  2015influential citation
• Pharmacogenetics of isoniazid-induced hepatotoxicity

  2015cites this paper
• Predictors, outcome, profile of anti-tubercular drug induced hepatitis – A prospective nested case - control study in a South Indian tertiary hospital

  2015cites this paper
• Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels

  2015cites this paper
• Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.

  2015influential citation
• Analysis of IL-6, STAT3 and HSPA1L Gene Polymorphisms in Anti-Tuberculosis Drug-Induced Hepatitis in a Nested Case-Control Study

  2015cites this paper
• Polymorphism of PXR gene associated with the increased risk of drug‐induced liver injury in Indonesian pulmonary tuberculosis patients

  2015cites this paper
• The association between HLA‐DQB1 polymorphism and antituberculosis drug‐induced liver injury: a Case–Control Study

  2015cites this paper
• Chapter 36 – Tuberculosis

  2014cites this paper
• PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

  2014cites this paper
• Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.

  2014cites this paper
• Studies on the mechanism of flucloxacillin-induced liver injury

  2014cites this paper
• Association of GSTM1, GSTT1 and CYP2E1 Gene Polymorphisms with Antituberculosis Drug Induced Hepatotoxicity in North Indian Population

  2014cites this paper
• N‐acetyltransferase 2, cytochrome P4502E1 and glutathione S‐transferase genotypes in antitubercular treatment‐induced hepatotoxicity in North Indians

  2014cites this paper
• Drug-Induced Liver Injury

  2014cites this paper
• A Theoretical Structural Study of Isoniazid Complexes with Thiotriazoline

  2014cites this paper
• Différenciation génétique des populations humaines pour les gènes de la réponse aux médicaments

  2014cites this paper
• Pharmacogenomics and Clinical Assessment of Drug-Induced Hepatotoxicity toward Improving Clinical Outcomes

  2014cites this paper
• Significant genotype difference in the CYP2E1 PstI polymorphism of indigenous groups in Sabah, Malaysia with Asian and non-Asian populations.

  2014cites this paper
• Recent progress in genetic variation and risk of antituberculosis drug‐induced liver injury

  2014cites this paper
• Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug–Induced Hepatotoxicity in Chinese Pediatric Patients

  2014cites this paper
• Drugs used in tuberculosis and leprosy

  2014cites this paper
• The CYP2E1 PstI Polymorphism in Indigenous Groups in Sabah, Malaysia

  2014cites this paper
• Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.

  2014cites this paper
• The Incidence of Liver Injury in Uyghur Patients Treated for TB in Xinjiang Uyghur Autonomous Region, China, and Its Association with Hepatic Enzyme Polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1

  2014cites this paper
• N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

  2014cites this paper
• A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?

  2014cites this paper
• The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients.

  2014cites this paper